Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).

[primary effusion lymphoma]

AIDS-related aggressive B cell lymphoma (HIV-NHL ) is the second most common HIV-associated malignancy . In contrast , Hodgkin-lymphoma (HL ) is one of the most common non-AIDS-defining malignancies . Current evidence-based recommendations for the treatment of HIV-associated lymphoma (HIV-lymphoma ) are not available . A panel of experts in the field of HIV-related lymphoma performed literature searches of the PubMed , Medline , and Cochrane databases . The consensus process was carried out as an e-mail and meeting-based discussion group . Six cycles of R-CHOP or R-EPOCH are standard of care for patients (pts ) with diffuse large B cell lymphoma (DLBCL ). Pts with Burkitt lymphoma and good performance status should receive dose-intensive regimens such as the GMALL B-ALL /NHL protocol . Standard therapy has not been defined for pts with plasmablastic and primary effusion lymphoma . Pts with lymphoma in sensitive relapse should receive high -dose chemotherapy followed by autologous stem cell transplantation . Stage - and risk adapted treatment yields high remission and survival rates in pts with HIV-HL similar to those achieved in HIV-negative HL pts . Combination antiretroviral therapy (cART ) should be applied concurrently to chemotherapy provided that pharmacokinetic interactions are being considered . Pts with HIV-lymphoma should usually be treated in an identical manner to HIV-negative patients .